biosimiar_wordcloudBiologic agents have been proven to be highly effective in treating inflammatory diseases; however, many health care plans restrict the use of these agents due to rising costs. In April 2016, the first biosimilar monoclonal antibody for inflammatory diseases, infliximab-dyyb, was approved by the FDA. Three additional biosimilars have been approved in the U.S. since and many others remain in developmental stages.

As with any newly approved treatment option, there are many important questions surrounding the details of biosimilars in treating inflammatory disease from clinicians and patients alike: What do the terms interchangeability and extrapolation mean for my practice? Are these agents as efficacious as their reference biologic?  How does the development and manufacture of a biosimilar compare to the original biologic? Can my patients expect to see a significant cost savings?  How does a clinician even go about ordering biosimilar agents?

Patients have also reported a significant lack of knowledge among clinicians on the topic of biosimilars and how they may be utilized to treat their inflammatory disease, while also decreasing cost of care.

CME Outfitters has created this Biosimilars Hub to provide the much needed education to clinicians and patients about these newly approved agents through an array of free online activities. The Biosimilars Hub offers clinicians the option to participate in short CME Snacks or an in-depth On Demand webcast to find the answers to the above questions and equip themselves with the knowledge necessary to confidently explain the interchangeability, efficacy, and safety of biosimilars to patients with inflammatory diseases.


Debating Interchangeability, Efficacy, and Safety of Biosimilars in the Management of Inflammatory Diseases

Tune into this CME Outfitters Webcast where Leonard Calabrese, DO answered questions received from participants on the various aspects of biosimilars. Gain valuable insights as Dr. Calabrese addresses real concerns and questions surrounding the use of biosimilars in the management of inflammatory diseases.

Participate Now!

CME Snacks

An Evolving Treatment Landscape for Inflammatory Disease: Involving Patients in the Discussion of Biosimilars

Involving the patient in the discussion surrounding the treatment and management of their disease is a vital part of achieving optimal outcomes. In this CME Snack, an expert faculty panel will discuss the various ways you can effectively engage the patient in the conversation regarding biosimilars and their treatment.

Watch Now!

An Evolving Treatment Landscape for Inflammatory Disease: The Role of Biosimilars in RA and IBD

What are the potential advantages of switching your patients with RA or IBD to a biosimilar? Are there any enhanced clinical benefits of biosimilar agents? What data exists to compare toxicity and immunogenicity of biosimilars to their reference agents? This CME Snack, featuring Dr. Calabrese and Dr. Cohen, focuses on the answers to these questions and more on treating your patients with rheumatoid arthritis and inflammatory bowel diseases.

Watch Now!

CME Outfitters On Demand

An Evolving Treatment Landscape for Inflammatory Disease: Debating Interchangeability, Efficacy, and Safety of Biosimilars

A significant gap exists in awareness and knowledge amongst health care providers on the topic of biosimilars, creating perceived barriers within clinical practices. It’s imperative that clinicians are well-versed on the data surrounding interchangeability, safety, and efficacy of biosimilar agents so that they may confidently select the optimal treatment plan for their patients. In this CME Outfitters On Demand activity, real patient responses are at the center of the conversation, with expert faculty highlight the patients’ concerns while engaging in an evidence-based discussion on a variety of aspects of biosimilars.

Watch Now!

Download These Free Biosimilars Resources for Use in Your Practice

Patient Resource

Biologics and Biosimilars: What Patients Need to Know
Download Now

Physician Resources

Scientific Considerations in Demonstrating Biosimilarity to a Reference Product
Download Now

Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product
Download Now

Biosimilar Biological Products
Download Now